Medtronic Q1 FY27 Beat Supports Buy Case at $90, but Litigation Risk Lingers

What happened

Medtronic reported Q1 FY27 results that exceeded expectations, with normalized revenue growth of 7% driven by strong Cardiovascular and Neuroscience segments. Management raised full-year revenue and EPS guidance, though margin expansion is expected to be gradual due to product mix shift toward higher-margin recurring revenues. This follows a period of caution due to competitive pressure in pulsed field ablation (PFA) and an adverse jury verdict with treble damages risk. Seeking Alpha initiated coverage with a buy rating and $106.33 price target, implying about 17% upside and a 3% dividend yield. The stock has pulled back to around $90, which is near the attractive entry level identified in prior analysis, suggesting operational strength may outweigh litigation-related overhang for now.

Implication

The Q1 FY27 beat and guidance raise validate the cardiovascular-led re-acceleration thesis, indicating PFA share gains and pricing stability may be holding despite Abbott Volt competition. The stock's pullback to approximately $90 offers an attractive entry relative to the base case implied value of $102 and the bull case of $115, providing a favorable risk/reward. However, the Applied litigation remains unresolved, with potential treble damages and injunctive relief that could create asymmetric downside if adverse rulings proceed. Margin expansion is expected to be gradual, so near-term earnings growth may lag revenue growth, requiring patience. Investors should monitor FY27 Q1 call transcripts and subsequent filings for updates on litigation posture and PFA pricing, and consider trimming if the stock approaches $105 as previously outlined.

Thesis delta

Thesis shifts from WAIT to BUY at current prices near $90, as Q1 FY27 results exceeded expectations and management raised guidance, addressing key concerns about growth durability. The operational beat reduces the probability of the bear case, but the unresolved Applied litigation and potential treble damages maintain an asymmetric risk that requires position sizing. Valuation at these levels now offers adequate margin of safety versus the base case, supporting a buy into strength with a trim discipline above $105.